Payment overview · 2025
General Payments
$268.01
15 reported records · 9 companies
Healthcare provider profile · identity verified
Cetin Hekimoglu, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MCMINNVILLE, TN · NPI 1568488708
Verified facts
What the public records show
CMS Open Payments records show Cetin Hekimoglu, MD received $268.01 in general payments during 2025 across 15 reported records.
Lilly USA, LLC accounted for 36.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Trelegy Ellipta, Tymlos.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 381 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 207 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Rybelsus by this doctor in 2024.
Radius Health, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tymlos as an associated drug or biological on 17199 records involving 7328 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Tymlos by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $97.34 | 36.3% | 6 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $34.78 | 13.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.97 | 12.3% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.88 | 8.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $21.85 | 8.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.95 | 6.0% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $14.53 | 5.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.51 | 5.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.20 | 5.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $268.01 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $97.34 | 6 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $34.78 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $32.97 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.02 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $21.88 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.51 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 381 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 159 | exact normalized | Medicare Part D |
| Tymlos tymlos |
2025 | Tymlos | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
159 | 49 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
71 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
381 | 73 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
207 | 54 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
47 | 19 |
| Radius Health, Inc. Exact reporting entity; no affiliate inference |
2025 | Tymlos open payments reported associated product |
CMS Open Payments — General Payments 17199 supporting records · 7328 recipient NPIs · example record 1249501587 |
Tymlos · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 690 | 229 |
| Amlodipine Besylate | Amlodipine Besylate | 413 | 140 |
| Mounjaro | Tirzepatide | 381 | 73 |
| Levothyroxine Sodium | Levothyroxine Sodium | 379 | 104 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 339 | 115 |
| Metformin Hcl | Metformin Hcl | 306 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 306 | 110 |
| Lisinopril | Lisinopril | 284 | 87 |
| Losartan Potassium | Losartan Potassium | 279 | 90 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 276 | 79 |
| Omeprazole | Omeprazole | 252 | 76 |
| Ozempic | Semaglutide | 207 | 54 |
| Trazodone Hcl | Trazodone Hcl | 198 | 65 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 159 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 137 | 43 |
| Furosemide | Furosemide | 123 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 118 | 40 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 116 | 34 |
| Carvedilol | Carvedilol | 113 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 111 | 32 |
| Alendronate Sodium | Alendronate Sodium | 110 | 40 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 110 | 30 |
| Doxycycline Hyclate | Doxycycline Hyclate | 108 | 90 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 107 | 41 |
| Meloxicam | Meloxicam | 105 | 48 |
| Montelukast Sodium | Montelukast Sodium | 105 | 35 |
| Sertraline Hcl | Sertraline Hcl | 104 | 34 |
| Pregabalin | Pregabalin | 100 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 95 | 24 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 95 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 93 | 42 |
| Risedronate Sodium | Risedronate Sodium | 93 | 43 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 91 | 31 |
| Levetiracetam | Levetiracetam | 87 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 23 |
| Prednisone | Prednisone | 81 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 80 | 24 |
| Cefadroxil | Cefadroxil | 76 | 61 |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | 27 |
| Eliquis | Apixaban | 74 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 21 |
| Celecoxib | Celecoxib | 72 | 37 |
| Famotidine | Famotidine | 71 | 26 |
| Jardiance | Empagliflozin | 71 | 26 |
| Ondansetron Hcl | Ondansetron Hcl | 70 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 68 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 67 | 21 |
| Ezetimibe | Ezetimibe | 64 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 27 |
| Nifedipine Er | Nifedipine | 58 | 17 |
| Allopurinol | Allopurinol | 56 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 54 | 12 |
| Benazepril Hcl | Benazepril Hcl | 54 | 14 |
| Cefdinir | Cefdinir | 54 | 43 |
| Mirtazapine | Mirtazapine | 54 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | 20 |
| Buspirone Hcl | Buspirone Hcl | 53 | 14 |
| Clonidine Hcl | Clonidine Hcl | 52 | 16 |
| Donepezil Hcl | Donepezil Hcl | 52 | suppressed |
| Potassium Chloride | Potassium Chloride | 49 | 17 |
| Farxiga | Dapagliflozin Propanediol | 48 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 15 |
| Dexlansoprazole Dr | Dexlansoprazole | 47 | 11 |
| Gabapentin | Gabapentin | 47 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | 16 |
| Rybelsus | Semaglutide | 47 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 17 |
| Atenolol | Atenolol | 45 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 43 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 38 |
| Promethazine Hcl | Promethazine Hcl | 42 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 41 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | 12 |
| Lovastatin | Lovastatin | 39 | suppressed |
| Memantine Hcl | Memantine Hcl | 39 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 39 | 21 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 38 | 19 |
| Methylprednisolone | Methylprednisolone | 38 | 33 |
| Mupirocin | Mupirocin | 37 | 30 |
| Nabumetone | Nabumetone | 36 | 21 |
| Simvastatin | Simvastatin | 36 | 13 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 36 | suppressed |
| Sucralfate | Sucralfate | 35 | 28 |
| Fenofibrate | Fenofibrate,micronized | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | 14 |
| Valsartan | Valsartan | 30 | suppressed |
| Fluconazole | Fluconazole | 29 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | 11 |
| Linzess | Linaclotide | 29 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | 24 |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 15 |
| Azithromycin | Azithromycin | 23 | 21 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Movantik | Naloxegol Oxalate | 22 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 20 |
| Vraylar | Cariprazine Hcl | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | 13 |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Felodipine Er | Felodipine | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 16 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Ubrelvy | Ubrogepant | 16 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 11 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | 15 |
| Bumetanide | Bumetanide | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Tymlos | Abaloparatide | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Ramelteon | Ramelteon | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 11 | suppressed |
| Mupirocin | Mupirocin Calcium | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $268.01 · 15 records | Lilly USA, LLC | Dexcom G6 Transmitter, EVENITY, MOUNJARO, NEXLETOL, Ohtuvayre, TRELEGY ELLIPTA, Tymlos, Veozah, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error